Get the Stockscreener App
1,218.44
1.44%
-17.12
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,218.44, with a volume of 1.76M.
It is down -1.44% in the last 24 hours and up +5.97% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,235.56
Open:
$1221.095
24h Volume:
1.76M
Relative Volume:
0.55
Market Cap:
$1.09T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
43.86
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+2.18%
1M Performance:
+5.97%
6M Performance:
+12.21%
1Y Performance:
+56.59%
1-Day Range:
$1,204.16
$1,241.89
1-Week Range:
$1,180.30
$1,249.45
52-Week Range:
$623.78
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,220.00 | 1.10T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.14 | 643.30B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
252.88 | 449.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
126.50 | 318.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.44 | 299.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity - 24/7 Wall St.
Eli Lilly (NYSE:LLY) Faces A Valuation Test - Kalkine Media
RBC stated that Eli Lilly and Co's obesity and diabetes drug businesses will drive second-quarter sales above expectations. - 富途牛牛
Truist raises Eli Lilly stock price target on incretin strength - Investing.com
Truist raises Eli Lilly stock price target on incretin strength By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,347 to $1,500 - Moomoo
Truist Securities Raises Price Target on Eli Lilly to $1,370 From $1,281, Keeps Buy Rating - Moomoo
Lilly Canada receives long-awaited Ebglyss® CDA-AMC recommendation as well as pCPA LOI for atopic dermatitis (eczema) - Newswire Canada
Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 - The Motley Fool
Eli Lilly (LLY) Stock Still Looks Below Fair Value Despite Rich Earnings - simplywall.st
Eli Lilly & Co. focuses on long-term growth as investors track its pipeline - AD HOC NEWS
Why Eli Lilly Stock Climbed to a Record High Today - AOL.com
Fla. Hospital Says Lilly's 340B Data Requirement Is Onerous - Law360
Migraine Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | GlaxoSmithKline, Merck, Pfizer, Bausch Health, Amgen, Abbvie, AstraZeneca, Eli Lilly - Barchart.com
Why Eli Lilly (LLY) Stock Is Trading Up Today - Yahoo Finance
Form 144 ELI LILLY AND COMPANY For: 7 July By Investing.com - Investing.com Canada
Lilly Endowment (LLY) reports multiple stock sales, May–June 2026 - Stock Titan
Tampa General sues Eli Lilly over alleged 'illegal' cutoff of discounted drug pricing - The Business Journals
Is Eli Lilly (NYSE:LLY) Still A Blue-Chip Leader? - Kalkine Media
Mounjaro from Eli Lilly and Co.weekly injection reshapes US weight-loss market - AD HOC NEWS
Eli Lilly Seen Raising Guidance on Continued GLP-1 Growth -- Market Talk - Moomoo
Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy? - The Motley Fool
Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up - Yahoo! Finance Canada
Eli Lilly and Co Stock (LLY) Moved Up by 3.08% on Jul 7: Facts Behind the Movement - TradingKey
Eli Lilly Gains as Investors Lean Into Obesity Franchise Momentum - Quiver Quantitative
Eli Lilly (LLY) Expands Mounjaro Use for Pediatric Diabetes Mana - GuruFocus
Eli Lilly (NYSE:LLY) Faces A Big GLP Test - Kalkine Media
LLY: JPMorgan Raises Eli Lilly Price Target Amid Strong Earnings Outlook - GuruFocus
Eli Lilly stock hits all-time high at 1238.06 USD By Investing.com - Investing.com Canada
LLY Maintained by JP Morgan -- Price Target Raised to $1400 - GuruFocus
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,350 to $1,400 - 富途牛牛
Can anyone catch up to Eli Lilly? - Pharma Voice
Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years. - Yahoo Finance
JPMorgan Adjusts Price Target on Eli Lilly to $1,400 From $1,300 - Moomoo
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - 富途牛牛
Eli Lilly stock holds the spotlight. Company identity is confirmed. - AD HOC NEWS
Eli Lilly (LLY) Could Be 19% Undervalued Following Medicare GLP 1 Expansion - simplywall.st
Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover - Yahoo Finance
LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill
What Eli Lilly Stock Said When It Had Too Much Business - Yahoo Finance
Eli Lilly (NYSE:LLY): Can GLP-1 Access Widen? - Kalkine Media
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges - Yahoo Finance
Cantor Fitzgerald raises Eli Lilly stock price target on strong outlook - Investing.com
Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) - Yahoo Finance
Eli Lilly and Company (LLY) Stock Analysis: Investor Outlook on a $1.08 Trillion Healthcare Giant - DirectorsTalk Interviews
Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board? - simplywall.st
LLYLilly(Eli) & Co Latest SEC Filings - Finviz
Eli Lilly Stock (LLY) Opinions on Medicare Coverage and Drug Pipeline Advancements - Quiver Quantitative
Eli Lilly and Co. | Pharmaceuticals, Biomedical Research, & Company - Encyclopedia Britannica
Should Expanded Medicare GLP‑1 Access and New Oncology Wins Require Action From Eli Lilly (LLY) Investors? - simplywall.st
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):